Recent studies showed that rituximab, a chimeric anti-CD20 monoclonal antibody, reduces antibody levels and ameliorates neuropathy in two thirds of patients with neuropathy and anti-myelin-associated glycoprotein (MAG) monoclonal IgM. Few data are available on the long-term effects of this therapy. We report on the long-term follow-up of rituximab responders with anti-MAG polyneuropathy.
Long-term effect of rituximab in anti-mag polyneuropathy
BRIANI, CHIARA;ZAMBELLO R;
2008
Abstract
Recent studies showed that rituximab, a chimeric anti-CD20 monoclonal antibody, reduces antibody levels and ameliorates neuropathy in two thirds of patients with neuropathy and anti-myelin-associated glycoprotein (MAG) monoclonal IgM. Few data are available on the long-term effects of this therapy. We report on the long-term follow-up of rituximab responders with anti-MAG polyneuropathy.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Neurology 2008_71,1742.pdf
Accesso riservato
Tipologia:
Published (Publisher's Version of Record)
Licenza:
Accesso privato - non pubblico
Dimensione
186.85 kB
Formato
Adobe PDF
|
186.85 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
